Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era

January 22, 2026

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

Topics Economy

January 14, 2026

Via Stocktwits

2 Bargain Stocks You Can Buy for Less Than $100 Right Now ↗

January 21, 2026

These stocks have struggled over the past year but may possess plenty of upside in the future.

Can it become the next biotech leader?

1 Stock That Could Soar by 175%, According to Wall Street ↗

January 21, 2026

Despite a challenging year, the company has a lot to look forward to in the coming years.

What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? ↗

January 20, 2026

As of January 19, 2026, the pharmaceutical landscape is being redefined by a single name: Eli Lilly and Company (NYSE: LLY). Once a steady, century-old stalwart known for its dominance in the insulin...

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 ↗

January 20, 2026

Via MarketBeat

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

The Trillion-Dollar Pharmacopeia: Eli Lilly’s (LLY) Dominance in the Age of Incretins

January 19, 2026

Via Finterra

Topics Economy

The Great Rotation: Small-Caps Log Longest Winning Streak Against S&P 500 Since 2019

January 12, 2026

As of mid-January 2026, the U.S. equity markets are witnessing a historic recalibration that few analysts predicted eighteen months ago. The Russell 2000 index, the benchmark for American small-cap...

What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale ↗

Topics Artificial Intelligence Economy Stocks

January 11, 2026

This clinical-stage biotech developing metabolic therapies reported a notable insider sale amid a challenging year for its stock.

As of January 9, 2026, Eli Lilly and Company (NYSE:LLY) has transitioned from a stalwart of the American pharmaceutical industry to a global financial phenomenon. Having recently crossed the historic...

Topics Regulatory Compliance

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Topics Earnings Economy Intellectual Property

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

Topics Artificial Intelligence Economy Intellectual Property

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

Small-Cap Slump: Russell 2000 Tumbles as Sticky Inflation Data Revives 'Higher-for-Longer' Fears

Topics Economy

January 07, 2026

The Russell 2000 index, the primary benchmark for American small-cap stocks, suffered a significant sell-off on Wednesday, January 7, 2026, as a batch of conflicting economic data sparked fears that...

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

Topics Artificial Intelligence Economy Stocks

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

As the first week of 2026 comes to a close, the financial markets are undergoing a significant structural shift. The broad-based "rising tide" that lifted almost all sectors throughout 2025 has begun...

Topics Economy

The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall

January 06, 2026

Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms ↗

Topics Artificial Intelligence Economy Stocks

January 05, 2026

Novo’s pricing applies to lower-dose oral Wegovy, with higher doses set at higher monthly prices.

Via Stocktwits

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

It's not time to give up on these companies yet.

Topics Economy Intellectual Property

2 Beaten-Down Stocks That Could Bounce Back in 2026 ↗

December 31, 2025

It's time for a celebration of the episodes that educated, amused, and enriched in 2025.

The Motley Fool Rule Breakers Besties of 2025 ↗

December 29, 2025

Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the...

The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill

December 25, 2025

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

Topics Economy Intellectual Property World Trade

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company...

Topics Economy Government Intellectual Property

The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era

December 24, 2025

Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded...

Topics Economy

Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market

December 23, 2025

NEW YORK — In a dramatic shift that has redefined the market landscape of 2025, small-cap stocks have surged to historic levels, signaling what many analysts are calling the "Great Rotation." On...

The Great Rotation: Small-Caps Break All-Time Highs as Investors Pivot from Mega-Tech

December 19, 2025

As of mid-December 2025, the long-awaited "Great Rotation" in the financial markets has shifted from a theoretical prediction to a dominant reality. For the better part of the last three years,...

Topics Artificial Intelligence Economy Initial Public Offering

The Great Rotation: Why the Russell 2000 is Finally Outpacing the Giants in Late 2025

December 18, 2025

Eli Lilly’s Oral Obesity Drug Passes Maintenance Test After Wegovy, Zepbound — Wall Street Flags Win For Viking Therapeutics ↗

Topics Artificial Intelligence Bonds Economy

December 18, 2025

Lilly’s Orforglipron is eligible for a fast-track review by the FDA in treating obesity.

Via Stocktwits

2 Growth Stocks to Invest $1,000 in Right Now ↗

December 18, 2025

These stocks have promising assets in their portfolios that could help make their valuations soar in the future.